abrdn Life Sciences Investors
HQL
41 hedge funds and large institutions have $47.6M invested in abrdn Life Sciences Investors in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 13 reducing their positions, and 11 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 13
9% more capital invested
Capital invested by funds: $43.8M → $47.6M (+$3.83M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.54% less ownership
Funds ownership: 13.28% → 12.74% (-0.54%)
16% less funds holding
Funds holding: 49 → 41 (-8)
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NIM
Needham Investment Management
New York
|
+$714K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$347K |
| 3 |
Cohen & Steers
New York
|
+$346K |
| 4 |
LPL Financial
San Diego,
California
|
+$344K |
| 5 |
FHA
Flagship Harbor Advisors
Boston,
Massachusetts
|
+$254K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$952K |
| 2 |
Citigroup
New York
|
-$441K |
| 3 |
AGM
Alpine Global Management
New York
|
-$437K |
| 4 |
DA
Doliver Advisors
Houston,
Texas
|
-$433K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$308K |
HQL Hedge Fund Activity: Q1 2017 in Review
41 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q1 2017, worth a combined $47.6M — up 8.7% from $43.8M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of HQL and 4 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 17 added.
The largest buyer was Needham Investment Management, adding an estimated $714K. The largest seller was First Trust Advisors, exiting entirely with an estimated $952K sold.
- 41 institutional investors held abrdn Life Sciences Investors (HQL) as of Q1 2017, down from 49 in Q4 2016.
- Funds reported $47.6M of abrdn Life Sciences Investors stock for Q1 2017, up 8.7% quarter-over-quarter.
- 4 funds opened new abrdn Life Sciences Investors positions in Q1 2017 and 11 closed out, a net change of -7 holders.
- The largest abrdn Life Sciences Investors buyer in Q1 2017 was Needham Investment Management, an estimated $714K added.
- The largest abrdn Life Sciences Investors seller in Q1 2017 was First Trust Advisors, an estimated $952K sold.
Based on aggregated 13F filings for Q1 2017.